FDA Expands Besremi to Adults With Essential Thrombocythemia

Company: PharmaEssentia · Drug: Besremi (Ropeginterferon Alfa-2b-njft) · Indication: Essential Thrombocythemia · Trial: SURPASS-ET (Phase III) · Date: August 31, 2026 Summary FDA approved ropeginterferon alfa-2b-njft, marketed as Besremi, for adults with essential thrombocythemia regardless of genotype or disease status. The decision creates a long-acting…